SCHEMBL4249088

SCHEMBL4249088

O=C(O)c1ccccc1Nc1ccccc1Cl

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.75
TTR P02766 3/20 0.73
MEN1 O00255 3/20 0.73
PTGS2 P35354 3/20 0.73
AKR1C3 P42330 3/20 0.73
KMT2A Q03164 3/20 0.73
ADORA3 P0DMS8 2/20 0.73
LMNA P02545 2/20 0.73
CYP1A2 P05177 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP2C9 P11712 2/20 0.73
HIF1A Q16665 2/20 0.73
USP2 O75604 1/20 0.73
MT-CO2 P00403 1/20 0.73
PLA2G1B P04054 1/20 0.73
PGR P06401 1/20 0.73
HTR1A P08908 1/20 0.73
ADRA2A P08913 1/20 0.73
AR P10275 1/20 0.73
MAPT P10636 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30575470 1.00 PBRM1 (0.75) PBRM1TTRMEN1PTGS2AKR1C3
SCHEMBL28297347 0.98 PBRM1 (0.73) PBRM1TTRMEN1PTGS2AKR1C3
SCHEMBL355549 0.88 FABP4 (0.80) PBRM1TTRMEN1PTGS2AKR1C3
SCHEMBL30320327 0.88 FABP4 (0.80) PBRM1TTRMEN1PTGS2AKR1C3
Clofenamic Acid SCHEMBL1477650 0.87 PBRM1 (0.73) PBRM1TTRMEN1PTGS2AKR1C3
Clofenamic Acid SCHEMBL29900200 0.87 PBRM1 (0.73) PBRM1TTRMEN1PTGS2AKR1C3
SCHEMBL6141546 0.87 PBRM1 (0.68) PBRM1TTRMEN1PTGS2AKR1C3
SCHEMBL6558595 0.87 PBRM1 (0.58) PBRM1TTRMEN1PTGS2AKR1C3
SCHEMBL30832916 0.87 PBRM1 (0.58) PBRM1TTRMEN1PTGS2AKR1C3
SCHEMBL21027562 0.86 PBRM1 (0.71) PBRM1TTRMEN1PTGS2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112812077-B Benzamide compound, preparation method thereof, pharmaceutical composition and application 中国科学院上海药物研究所 2023-08-22 CN disclosed
CN-108499614-B Method for preparing drug intermediate for central nervous system from modified nickel catalytic material 西南医科大学附属医院 2021-06-04 CN disclosed
CN-112812077-A Benzamide compound and preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2021-05-18 CN disclosed
CN-105764883-B Thermoplastic polymer composition 美利肯公司 2019-06-04 CN disclosed
US-9718821-B2 Pyridopyrimidinone inhibitors of kinases ABBVIE INC. (US) 2017-08-01 US disclosed
EP-2817308-B1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC (US) 2016-09-07 EP disclosed
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION CHOUDHARY MUHAMMAD IQBAL (PK) 2015-02-19 US disclosed
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION CHOUDHARY MUHAMMAD IQBAL (PK) 2015-02-19 US disclosed
CN-104271576-A Pyridopyrimidinone inhibitors of kinases ABBVIE INC 2015-01-07 CN disclosed
EP-2817308-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES AbbVie Inc. (US) 2014-12-31 EP disclosed
US-20130225589-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC. (US) 2013-08-29 US disclosed
WO-2013126656-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC. (US) 2013-08-29 WO disclosed
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-05-21 US disclosed
US-4168312-A Quinolone derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1979-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION AGER, NFKBIA, DNPEP PBRM1 4370/4885TTR 843/4885MEN1 3683/4885
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME CLIC1, ASIC1, CLIC4 PBRM1 2684/4885TTR 4783/4885MEN1 2715/4885
US-20130225589-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES WEE1, WEE2, CDK1 PBRM1 696/4885TTR 4725/4885MEN1 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.